Navigation Links
Medifast, Inc. Announces Acceptance for Publication of Clinical Efficacy Study
Date:10/15/2007

Study of Medifast's effectiveness for weight control in patients with type

2 diabetes has been accepted for publication

OWINGS MILLS, Md., Oct. 15 /PRNewswire-FirstCall/ -- Medifast, Inc. (NYSE: MED) today announced that a study conducted by researchers at the Johns Hopkins University Bloomberg School of Public Health has been accepted for publication in a peer-reviewed journal which is scheduled for release in an early 2008 issue. The study compared Medifast's effectiveness for weight control to the standard American Diabetes Association (ADA) recommended dietary guidelines.

"Weight loss is critical for controlling type 2 diabetes," said Michael S. McDevitt, Chief Executive Officer, Medifast, Inc. "Medifast is proud that our products are effective for people who suffer from this disease, and we will continue to work toward improving the health of people with type 2 diabetes."

For more than 25 years Medifast has been prescribed by practitioners as a safe and effective program that yields significant results either alone, or as a complementary low-calorie program with drug therapy. The Medifast brand will be further validated in the medical community, and by consumers, by a second new study recently submitted for publication. The second study which was conducted by researchers at a major university medical institution, shows favorable findings for the Medifast Program among individuals on appetite suppressant therapy.

The Medifast Program alone is proven to provide significant weight loss of 2-5 pounds per week. While the Company does not recommend the use of weight loss drugs, Medifast does recognize that diet pills are very much part of the landscape now and in the future. Medifast is a proven program that can ensure consumers are successful on drug therapy regimens that include a reduced calorie diet and lifestyle change in order to be effective. Medifast also works well with the current popular over-the-counter drug that recommends utilizing a low fat program.

The findings from studies at two university medical institutions only add to the medically approved history of the Medifast Program. Medifast has been recommended by over 15,000 physicians nationwide, and provides its customers with a network of health coaches and nutrition experts as well as a vast online support community.

More information regarding the inclusion of studies in peer-reviewed journals will become available at the time of publication.

About Medifast:

Medifast (NYSE: MED) is the leading easy-to-use, clinically proven portion-controlled weight loss program. Medifast has been recommended by 15,000 physicians and used by over one million customers. It is committed to enriching lives by providing innovative choices for lasting health. Medifast programs have been proven effective through studies by major university teaching hospitals. The company sells its products and programs via four unique distribution channels: 1) the web and national call centers, 2) national network of physicians, 3) medically supervised Medifast Weight Control Centers and 4) the Take Shape For Life direct-selling division, a network of health coaches. Medifast was founded in 1980 and is located in Owings Mills, Maryland. For more information log onto http://www.ChooseMedifast.com.


'/>"/>
SOURCE Medifast, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
Breaking Medicine Technology:
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
Breaking Medicine News(10 mins):